The Asia Pacific drug delivery systems market is expected to reach US$ 441,337.0 Mn in 2027 from US$ 212,012.7 in 2018. The market is estimated to grow with a CAGR of 8.6% from 2019-2027.
The key factors that are driving the growth of the market are rising incidence of chronic diseases, and growing demand for non-invasive drug delivery devices. However, the factors restraining the market growth are high R&D cost involved in product development. Whereas, high cost for developing drug delivery devices is likely to have a negative impact on the growth of the market in the coming years.
In Asia Pacific, various routes of administration are being studied in order to treat these chronic diseases. According to the estimates by The Asia Pacific Burden of Disease, the death rate of CVD is approximately 272 per 100,000 people in India, which is comparatively higher than the Asia Pacific average (i.e., 235 per 100 000 population). Similar trends for the increased prevalence of diabetes is witnessed among Asian countries such as Australia, China, South Korea, and Australia. For instance, as per IDF Diabetes Atlas published by the International Diabetes Federation in 2017, South-East Asia consists of almost one-fifth (19%) of the Asia Pacific diabetes population. As per the data published by the World Health Organization (WHO), in 2014, around 230 million people in China had CVD. Also, by 2030, the number is predicted to increase by 50% considering the aging Chinese population and growth. Additionally, by 2030, cardiovascular disease will cost $ 1,044 billion to the Chinese government. Rising geriatric population and related chronic diseases are expected to drive the sales of medical devices, hence leading to the growth of the market in the Asia Pacific over the forecast years. The problem of growing prevalence of cancer is increasing in APAC. The region reports Japan, Taiwan, Singapore, South Korea, Malaysia, Thailand, China, Philippines, Sri Lanka, Vietnam, Indonesia, Mongolia, India, Laos, and Cambodia as the top 15 countries with cancer prevalence. Owing to Increasing Chronic Diseases Cases, the drug delivery systems market is likely to propel the growth in the forecast period.
China is anticipated to lead the adoptions of drug delivery systems across the Asia Pacific region through the forecast period. Growing research activities in drug delivery technology, increasing significant prevalence of disease and rising number of collaborations and partnerships in advance science and innovation. China is also expected to provide lucrative opportunities to local as well as international players to manufacture and market drug delivery devices in the country over the forecast years.
Exhibit: China Drug Delivery Systems Market Revenue and Forecasts to 2027 (US$ Mn)

Asia Pacific Drug Delivery Systems Market Segmentation
By Route of Administration
Companies Mentioned
| Report Attribute | Details |
|---|---|
| Market size in 2018 | US$ 212,012.7 Million |
| Market Size by 2027 | US$ 441,337.0 Million |
| CAGR (2019 - 2027) | 8.6% |
| Historical Data | 2016-2017 |
| Forecast period | 2019-2027 |
| Segments Covered |
By Route of Administration
|
| Regions and Countries Covered |
Asia-Pacific
|
| Market leaders and key company profiles |
|
The Asia Pacific Drug Delivery System Market is valued at US$ 212,012.7 Million in 2018, it is projected to reach US$ 441,337.0 Million by 2027.
As per our report Asia Pacific Drug Delivery System Market, the market size is valued at US$ 212,012.7 Million in 2018, projecting it to reach US$ 441,337.0 Million by 2027. This translates to a CAGR of approximately 8.6% during the forecast period.
The Asia Pacific Drug Delivery System Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Asia Pacific Drug Delivery System Market report:
The Asia Pacific Drug Delivery System Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Asia Pacific Drug Delivery System Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Asia Pacific Drug Delivery System Market value chain can benefit from the information contained in a comprehensive market report.
Please tell us your area of interest
(Market Segments/ Regions and Countries/ Companies)